Article in Biomarkers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors at 3 institutions in 1 country.
Akif AltinbasDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0003-2611-1596
Jacinta A HolmesDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.
Shadi SalloumDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.
Anna LidofskyDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-6864-4476
Nadia AlatrakchiDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.
Ma SomsoukDepartment of Medicine, University of California San Francisco, School of Medicine, San Francisco, CA 94143, USA.ORCID 0000-0002-4571-4870
Peter HuntDepartment of Medicine, University of California San Francisco, School of Medicine, San Francisco, CA 94143, USA.ORCID 0000-0002-4571-4870
Steven DeeksDepartment of Medicine, University of California San Francisco, School of Medicine, San Francisco, CA 94143, USA.ORCID 0000-0001-6371-747X
Kara W ChewDepartment of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Georg LauerDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.
Annie KrugerDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-8227-5996
Wenyu LinDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-9913-9683
Raymond T ChungDepartment of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, MA 02114, USA.
Harvard University · USUniversity of California, San Francisco · USUniversity of California, Los Angeles · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
Cooperative mechanisms of HIV-enhanced liver fibrogenesis in HBV CoinfectionR01AI155140 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, LIN, WENYU · 2020 to 2025
$3.5M
HIV-induced monocyte and macrophage perturbations driving liver fibrogenesisR56DK134251 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ALATRAKCHI, NADIA, CHUNG, RAYMOND T · 2022 to 2022
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
LOXL-2 and TNC-C are markers of liver fibrogenesis in HCV/HIV-, HIV- and HCV-infected patients. · full record | OpenQuestion